If you missed the broadcast in January, you can now view the recording from this YouTube Live Event. Listen in as Dr. William Dahut from NCI and Dr. Heather Cheng of the University of Washington discuss treatment options, current research, and directions for future research.
Results from a phase III clinical trial suggest that a targeted drug that is linked to a radioactive isotope to help kill tumor cells may soon be a new treatment option for some patients with advanced neuroendocrine tumors (also known as NETs.)
Results of a randomized clinical trial show that pembrolizumab extended the length of time patients with advanced non-small cell lung cancer lived before their disease got worse.
Results of a phase III clinical trial show that people with cancer that has spread to their bones can receive less-frequent treatments of zoledronic acid to prevent bone fractures and other complications.
Clinical Trials Information for Patients and Caregivers
This phase II trial studies how well FAST MRI and 3D mammography work in finding cancer in women 40 to 75 years-old with dense breasts. Combined screening with these two imaging tools may be a better method to screen women with dense breasts.
ALCHEMIST is a group of randomized clinical trials for patients with early-stage non-small cell lung cancer whose tumors have been completely removed by surgery. These trials test to see if adding targeted therapy based on tumor genetics will help prevent the cancer from returning and increase the number of people who may live longer.
This phase II trial is for patients with previously treated breast, head and neck, non-small cell lung, or urothelial cancer that has spread to distant parts of the body or cannot be removed by surgery. It tests how well two experimental drugs, 5-fluoro-2-deoxycytidine and tetrahydrouridine, work together.